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Sintamil *(nitroxazepin hydrochloride) 
is a new antidepressant with the following 
chemical structure—10 (3-Dimethylamino 
propyl)-2-nitro-dibenz (b,f,) - 1,4,-oxazepin 
11 (10 H).— one hydrochloride. This 
compound has been investigated in both 
animals and humans for its antidepressant 
activity with impressive results. The overall 
positive response to Sintamil therapy was 
observed in 73.1% in a combined group of 
patients with all types of depressions. 
(Gupta and Mankodi, 1972). It has been 
reported to be equally effective as Imi-
pramine and Triimipramine in the treat-
ment of depression. Furthermore, it is 
extremely well tolerated with a lesser number 
of patients experiencing a lesser number of 
side effects in comparison to both Imi-
pramine and Triimipramine. 
A common practice in the pharmaco-
therapy of depressive illness is to prescribe 
the antidepressant drug in three divided 
doses. However, in recent years pharma-
cological and clinical studies have shown 
that prescribing a single daily dose of anti-
depressants is scientifically sound. Absorp-
tion of these drugs after oral administration 
is remarkably prompt—maximum absorp-
tion taking place in the first 30 to 60 minutes. 
However, since they have a long biological 
half life (Dimascio and Schader, 1969) 
the drug accumulates in the body tissues 
from. where it is released slowly. 
. Furthermore, since it is now known 
that a considerable number of Psychiatric 
patients (both in-patients and out-patients) 
fail to take their medication in the pre-
scribed dose (Park and Lipman, 1964, Willcox 
el al. 1965, Hare and Willcox, 1967), a 
single daily dose regimen is more likely 
to be taken reliably than the thrice daily 
dosage (General practitioners clinical trial, 
1970, Hussain and Choudhary, 1973, 
Blackwell, 1976). Other reported ad-
vantages of the single daily dose are— 
increased convenience for both the patients 
and nursing staff, avoidance of certain side 
effects such as the transient drowsiness 
occurring after oral intake which is trouble-
some during the day, but is useful in pro-
moting sleep when given in a single bed 
time dose. Finally a single dose is also more 
economical than its equal amount dispensed 
in divided doses. 
In view of these reports it was decided 
to carry out a double blind study to com-
pare the efficacy and tolerability of a single 
bed tktte dose of Sintamil with that of an 
equal amount of drug given in three divided 
doses, in the treatment of depression. 
MATERIAL AND METHOD 
The total sample consisted of 57 patients 
attending the Psychiatric department of 
Rajendra Hospital, Patiala and diagnosed 
as suffering from a depressive illness. This 
include cases of (a) Endogenous depression, 
i.e. Manic-depressive psychosis-depressed 
and Involutional Malancholia. (I.C.D. No. 
296) and (b) Reactive depressions, i.e. 
Depressive neruosis (I.C.D. No. 300.4). 
8 subjects failed to complete the minimum 
4 week trial period, so that the present 
report is based on a total of 49 cases. There 
were 28 males 21 females ranging in age 
from 16 to 64 years with a mean age of 
39.2 years. Patients with a history of other 
psychiatric illness including alcohol and 
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drug dependence, evidence of organic dis-
ease, or with a history of intake of drugs 
known to produce depression and pregnant 
women were excluded from the study. 
The patients were randomly assigned 
on a double blind basis to the two treatment 
groups, i.e. (a) The single daily dose (S.D.) 
group (25 subjects) who received 75 mgm. 
of Sintamil at bed time, and matching 
placebo tablets in the morning and after-
noon, and (6) the divided dose (D.D.) group 
(24 subjects) who received 25 mgm Sintamil 
t.i.d. during the first four weeks of the 
trial. In case of those who were not re-
covered at the end of the 4 week trial, the 
dose was increased to 150 mgm. daily either 
as a single bed time dose or in three divided 
doses after opening the code. They were 
followed up for a minimum of two weeks 
on this dose. 
No other drug was given during the 
trial period, however if considered neces-
sary a day time tranquillizer (diazepam) 
or a hypnotic (nitrazepam) was added. 
All adverse effects reported by the^patient 
were recorded, with their day of onset and 
severity. Psychiatric assessments in the form 
of Hamilton Rating Scale for depression 
(Hamilton, 1960) and a Clinical Global 
Impression was recorded at weekly intervals 
throughout the period of study. 
RESULTS 
The distribution of patients in the S.D. 
group and the D.D. group according to 
age, sex, duration and type of illness is shown 
in Table 1. 
Therapeutic Effects 
Table 2 shows the group Hamilton 
Rating Scale scores (HRS) for the two 
groups separately, starting with the initial 
(pretreatment) score and at weekly intervals 
thereafter. Improvement was assessed as 
the precentage reduction in the global score 
from the initial score. It is seen that by the 
end of the 4th week there was a 71.2% 
reduction in the HRS score in the S. D. 
TABLE 1—Characteristics of the Single daily 
dose (S. D.) group and the divided dose 
(D.D.) group) 
Characteristics 
Age : 
Range 
Mean and S.D. 
Sex : 
Males 
Females 
Type of illness : 
Endogenous 
Reactive 
Duration of illness 
Mean and S.D. 
S.D. group 
N=25 
16—64 yrs. 
39.7J-13.2 
15 
10 
16 
9 
: 
8.4 months±7.2 
D.D. group 
N=24 
18+60 yrs. 
38.6^-11.6 
13 
11 
18 
6 
6.8 months^^ 
TABLE 2—Comparison of the group scores on 
the Hamilton RatingScales for the initial 
4 week trial period. 
Period 
S.D. group D.D. group . 
Total %agc Total %age 
score reduc- score reduc-
N=25 don in N=24 tion in 
score score 
Initial (pre-
treatment) 
First week 
Second week 
Third week 
Fourth week 
427 —  373 
283 33.7% 286 23.3 
196 54.1% 216 42.1 
163 61.8% 160 57.1 
123 72.1% 116 68.9 
group as compared to a reduction of 68.9% 
in the D. D. group. The reduction in the 
group HRS score thus being almost the 
same in both the groups. 
Table 3 shows the individual response 
of patients in the S.D. and D.D. groups at 
4 weeks and 6 weeks, as measured in terms 
of percentage reduction in the HRS scores 
and on clinical global assessment. At the 
end of 4 weeks on a ffxed daily dose of 75 SINTAMIL IN THE TREATMENT OF DEPRESSION  197 
TABLE 3—Showing the individual patient response in the S. D. and D. D. groups measured as 
percentage reduction in H. R. S. score and on clinical global assessment 
Experimental group 
Percentage reduction in HRS score at 4 weeks on 
75 mgm./day 
up to 24  25—49  50—74  75—100 
Clinical assessment 
at 4 weeks 
— on 75 
mgm/day 
clinically 
recovered 
' at 6 weeks** 
on 150 
mgmjday 
clinically 
recovered 
Single daily 
dose N=25 
Divided dose 
N=24 
1 
4% 
3 
13% 
2 
8% 
3 
13% 
4 
16% 
7 
29% 
18 
72% 
11 
46% 
11 
44% 
9 
37.5% 
22 
88% 
19 
79.1% 
*At 4 weeks ;X» =0.21, d.f. = l, N.S. 
** At 6 weeks : X« 0.69, d.f.= l, N.S. 
mgm. a day the number of patients who 
were clinically recovered was 11 (44%), 
in the S. D. group, and 9 (37.5%) in the 
D.D. group. This difference is not statis-
tically significant. After a further two 
weeks treatment on an incresaed dose of 
150 mgm. a day the number clinically 
recovered rose to 22 (88%) in the S. D. 
group, and 19 (79%) in the D.D. group. 
Here again the response rate is slightly 
better in the S. D. group, but the difference 
is not statistically significant. 
Adverse Effects 
9 out of the 25 subjects in the S.D. 
group (36%), reported a total of 16 side 
effects, whereas in the D.D. group 7 out of 
24 (29%) complained of a total of 13 side 
effects related to the use of the drug during 
the trial period. A list of all the adverse 
effects reported is given in Table 4. It is 
apparent that dryness o*" mouth and consti-
pation are the only two common complaints, 
reported by 9 (18.3%) and 7 (14.3%) sub-
jects respectively. Although the total num-
ber o
f side effects observed in the two groups 
is similar, there does seem to be a difference 
in the frequency of occurrence of specific 
symptoms, e.g. dryness of mouth and dizzi-
ness is observed more commonly among 
the divided dose group, while constipation, 
palpitation, restlessness and blurred vision 
are marginally more among the single daily 
dose group. 
Concomitant therapy 
Concomitant therapy in the form of 
tranquillizers and/or hypnotics had to be 
given to 10 patients in the S.D. group (40%), 
and to 9 patients in the D.D. group (37.5%). 
In the S.D. group, 7 patients were given 
additional tranquillizers alone, 2 hypontics 
alone and 1 was given both a daytime 
tranquillizer as well as a hypnotic. In the 
D.D. group 5 were given tranquillizers 
only, 3 hypnotics only and 1 both a tran-
TABLE 4—Showing number of patients reporting 
side effects in the two treatment groups 
Side effects 
Dryness of moutn 
Constipation 
Dizziness 
Heaviness of head 
Palpitation 
Irritability 
Blurred vision, Vomiting, 
tus , Burning in abdomen, 
lessness. 
Tini-
Rest-
S.D. 
Group 
3 
5 
0 
1 
2 
0 
1 each 
D.D. 
group 
6 
2 
3 
1 
0 , 
1 
Nil 
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quillizer plus a hypnotic. Thus 3 patients 
in the S.D. group needed a bed-time hyp-
notic as compared to 4 in the D.D. group. 
Apparently, Sintamil does not have much 
sedative activity as in the case of some other 
tricyclic antidepressants which, when given 
in a single bed-time dose are reported to 
promote sleep and thus render the pres-
cription of a hypnotic unnecessary (Hussain 
and Chaudhary, 1973). 
DISCUSSION 
The findings of the present study 
support the hypothesis that a single daily 
dose of an antidepressant is as effective as 
the same amount of the drug given in divided 
doses. These results are similar to those of 
Kramer (1962), Hussain and Chaudhary 
(1973). Being a new drug which had not 
previously been given in large single doses, 
it was decided to put all patients on a fixed 
daily dose of 75 mgm. of Sintamil for the 
first 4 weeks of the trial, at which time in 
the absence of any serious side effects the 
dose could be increased to 150 mgm daily 
in those patients who failed to respond 
to the smaller dose. At the end of the 4 
week trial period we obtained almost 
identical reductions in the group Hamilton 
Rating Scale scores—the percentage reduc-
tion being 71.2% in the S.D. group, and 
68.9% in the D.D. group. On clinical 
global assessment also the response rates in 
the two groups are almost the same—44% 
in S.D. group and 37.5% in the D.D. group. 
At the end of 6 weeks the recovery rates 
had increased to 88% in the S.D. group 
and 79% in the D.D. group. The overall 
response rate to Sintamil therapy in the 
present study is found to be 82%—which 
is somewhat higher than the rate of 71.1% 
reported by Gupta and Mankodi (1972) 
for a mixed group of patients treated with 
Sintamil. 
Adverse side effects from Sintamil in-
take were complained of by less than a third 
of all the subjects in the present study. 
(36% in the S.D. group, and 29% in the 
D.D. group) and the side effects were 
generally mild and did not necessitate 
stoppage of treatment in any case. This is 
again in conformity with earlier reports 
of a lower frequency of adverse effects on 
Sintamil as compared to other tricyclic 
anti-depressants. (Gupta and Mankodi, 
1972). The findings that dryness of mouth 
and dizziness were more common in the 
divided dose subjects is of interest since it 
tends to occur within the first two or three 
hours after oral ingestion of the drug. On 
the other hand constipation was more 
common with the single bed-time dose 
administration. 
In conclusion, it can be stated that 
Sintamil appears to be equally effective as 
an antidepressant both when given in a 
single bed-time dose or in the traditional 
three divided doses. Furthermore, it has 
relatively few side effects, and the more 
troublesome ones of dryness of mouth and 
dizziness are considerably less with the 
single night time dosage schedule. Finally, 
a single daily dose given at bed time is more 
convenient and likely to increase patient 
compliance as compared to the thrice a day 
schedule. 
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